Biotechnology company Alchemab Therapeutics and Medicines Discovery Catapult (MDC) have received $2.06m (£1.7m) grant from Innovate UK to accelerate the development of disease modifying therapy to treat Huntington’s disease.
Biotechnology company Gilgamesh Pharmaceuticals has raised $39m in Series B financing round, led by Prime Movers Lab, for advancing treatments for mental health.
Innovent Biologics and LG Chem Life Sciences have signed an agreement for the latter’s late-stage novel non-purine xanthine oxidase inhibitor (XOI) Tigulixostat for the chronic management of hyperuricemia in individuals with gout disease.
Merck has initiated a cash tender offer, through a subsidiary, to acquire all outstanding shares of common stock of Imago BioSciences.
Chinese company HitGen has signed a research agreement with biopharmaceutical firm Nitrase Therapeutics to discover DNA-encoded library-based drug.
US-based biotechnology firm Rallybio has entered into a strategic alliance with AbCellera to discover, develop, and commercialise new antibody-based therapeutics for rare diseases.
Gene editing company iECURE has raised $65m in a Series A-1 financing round to advance in vivo programmes to treat rare paediatric liver diseases.
Harbour BioMed’s wholly owned subsidiary Nona Biosciences and global biotechnology firm ModernaTX have entered into a license and collaboration deal for the development of immunotherapies.
Navrogen has signed a cooperative research and development agreement (CRADA) with the US National Cancer Institute (NCI) researchers for the clinical development of NAV-001.
Amgen has reported positive end-of-treatment data from the Phase II OCEAN(a)-DOSE study of its investigational olpasiran (formerly AMG 890).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.